Regulation of growth hormone signaling by selective estrogen receptor modulators occurs through suppression of protein tyrosine phosphatases

Endocrinology

Volumn 148, Issue 5, 2007, Pages 2417-2423

  Leung, Kin Chuen ^a,b   Brce, Jesena ^a   Doyle, Nathan ^a   Lee, Heather J ^a   Leong, Gary M ^a,c,d   Sjögren, Klara ^a,e   Ho, Ken K Y ^a  

^a ST VINCENT S HOSPITAL   (Australia)

^b GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d MATER CHILDREN S HOSPITAL   (Australia)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; DACTINOMYCIN; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; GROWTH HORMONE; GROWTH HORMONE RECEPTOR; JANUS KINASE 2; LUCIFERASE; PROTEIN SH2; PROTEIN TYROSINE PHOSPHATASE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STAT5 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 2; VANADIC ACID; ANTIESTROGEN; ESTROGEN; ESTROGEN RECEPTOR; HUMAN GROWTH HORMONE; PROTEIN SYNTHESIS INHIBITOR; PROTEIN TYROSINE PHOSPHATASE SHP 1; PROTEIN TYROSINE PHOSPHATASE, NON RECEPTOR TYPE 11; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; PTPN6 PROTEIN, HUMAN; SIGNAL PEPTIDE; SOCS2 PROTEIN, HUMAN; SUPPRESSOR OF CYTOKINE SIGNALING; TAMOXIFEN; UNCLASSIFIED DRUG;

ARTICLE; ATTENUATION; BREAST CANCER; CANCER CELL; CELL TYPE; CONTROLLED STUDY; DRUG INHIBITION; EMBRYO; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HORMONAL REGULATION; HUMAN; HUMAN CELL; KIDNEY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SRC HOMOLOGY DOMAIN; BREAST TUMOR; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; KIDNEY; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; DACTINOMYCIN; ESTROGEN ANTAGONISTS; ESTROGENS; HUMAN GROWTH HORMONE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; JANUS KINASE 2; KIDNEY; PROTEIN SYNTHESIS INHIBITORS; PROTEIN-TYROSINE-PHOSPHATASE; RALOXIFENE; RECEPTORS, ESTROGEN; SHP1 PROTEIN TYROSINE PHOSPHATASE; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TAMOXIFEN;

EID: 34249807362     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2006-1305     Document Type: Article

References (47)

1. Leung K-C, Johannsson G, Leong GM, Ho KKY 2004 Estrogen regulation of growth hormone action. Endocr Rev 25:693-721
2. Herrington J, Carter-Su C 2001 Signaling pathways activated by the growth hormone receptor. Trends Endocrinol Metab 12:252-257
3. Woelfle J, Billiard J, Rotwein P 2003 Acute control of insulin-like growth factor-I gene transcription by growth hormone through Stat5b. J Biol Chem 278:22696-22702
4. Woelfle J, Chia DJ, Rotwein P 2003 Mechanisms of growth hormone (GH) action. Identification of conserved Stat5 binding sites that mediate GH-induced insulin-like growth factor-I gene activation. J Biol Chem 278:51261-51266
5. Alexander WS 2002 Suppressors of cytokine signalling (SOCS) in the immune system. Nat Rev Immunol 2:1-7
6. Klingmuller U, Lorenz U, Cantley LC, Neel BG, Lodish HF 1995 Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell 80:729-738
7. Ram P, Waxman DJ 1997 Interaction of growth hormone-activated STATs with SH2-containing phosphotyrosine phosphatase SHP-1 and nuclear JAK2 tyrosine kinase. J Biol Chem 272:17694-17702
8. Stofega MR, Herrington J, Billestrup N, Carter-Su C 2000 Mutation of the SHP-2 binding site in growth hormone (GH) receptor prolongs GH-promoted tyrosyl phosphorylation of GH receptor, JAK2 and STAT5B. Mol Endocrinol 14:1338-1350
9. Weissberger AJ, Ho KKY, Lazarus L 1991 Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor-I, and GH-binding protein in postmenopausal women. J Clin Endocrinol Metab 72:374-381
10. O'Sullivan AJ, Crampton LJ, Freund J, Ho KKY 1998 The route of estrogen replacement therapy confers divergent effects on substrate oxidation and body composition in postmenopausal women. J Clin Invest 102:1035-1040
11. Kam GYW, Leung K-C, Baxter RC, Ho KKY 2000 Estrogens exert route- and dose-dependent effects on insulin-like growth factor (IGF)-binding protein-3 and the acid-labile subunit of the IGF ternary complex. J Clin Endocrinol Metab 85:1918-1922
12. Wolthers T, Hoffman DM, Nugent AG, Duncan MW, Umpleby M, Ho KKY 2001 Oral estrogen antagonizes the metabolic actions of growth hormone (GH) in GH deficient women. Am J Physiol 281:E1191-E1196
13. McDonnell DP, Wijayaratne A, Chang C-Y, Norris JD 2002 Elucidation of the molecular mechanism of action of selective estrogen receptor modulators. Am J Cardiol 90(Suppl):35F-43F
14. Bryant HU 2002 Selective estrogen receptor modulators. Rev Endocr Metab Disord 3:231-241
15. Pollak MN, Huynh HT, Lefebvre SP 1992 Tamoxifen reduces serum insulin-like growth factor I (IGF-I). Breast Cancer Res Treat 22:91-100
16. Decensi A, Bonannt B, Guerrieri-Gonzaga A, Gandint S, Robertson C, Johansson H, Travaglini R, Sandri MT, Tessadrelli A, Farante G, Salinaro F, Bettega D, Barreca A, Boyle P, Costa A, Veronesi U 1998 Biologic activity of tamoxifen at low doses in healthy women. J Natl Cancer Inst 90:1461-1467
17. Oleksik AM, Duong T, Pliester N, Asma G, Popp-Snijders C, Lips P 2001 Effects of the selective estrogen receptor modulator, raloxifene, on the somatotropic axis and insulin-glucose homeostasis. J Clin Endocrinol Metab 86:2763-2768
18. Torrisi R, Baglietto L, Johansson H, Veronesi G, Bonanni B, Guerrieri-Gonzaga A, Ballardini B, Decensi A 2001 Effect of raloxifene on IGF-I and IGFBP-3 in postmenopausal women with breast cancer. Br J Cancer 85:1838-1841
19. Attanasio R, Barausse M, Cozzi R 2003 Raloxifene lowers IGF-I levels in acromegalic women. Eur J Endocrinol 148:443-448
20. Dimaraki EV, Symons KV, Barkan AL 2004 Raloxifene decreases serum IGF-I in male patients with active acromegaly. Eur J Endocrinol 150:481-487
21. Weissberger AJ, Ho KK 1993 Activation of the somatotropic axis by testosterone in adult males: evidence for the role of aromatization. J Clin Endocrinol Metab 76:1407-1412
22. De Marinis L, Mancini A, Izzi D, Bianchi A, Giampietro A, Fusco A, Liberale I, Rossi S, Valle D 2000 Inhibitory action on GHRH-induced GH secretion of chronic tamoxifen treatment in breast cancer. Clin Endocrinol (Oxf) 52:681-685
23. Mandala M, Moro C, Ferretti G, Calabro MG, Nole F, Rocca A, Munzone E, Castro A, Curigliano G 2001 Effect of tamoxifen on GH and IGF-1 serum level in stage I-II breast cancer patients. Anticancer Res 21:585-588
24. Carmignac DF, Gabrielsson BG, Robinson ICAF 1993 Growth hormone binding protein in the rat: effects of gonadal steroids. Endocrinology 133:2445-2452
25. Leung KC, Doyle N, Ballesteros M, Sjögren K, Watts CKW, Low TH, Leong GM, Ross RJM, Ho KKY 2003 Estrogen inhibits GH signaling by suppressing GH-induced JAK2 phosphorylation, an effect mediated by SOCS-2. Proc Natl Acad Sci USA 100:1016-1021
26. Ho KY, Weissberger AJ, Stuart MC, Day RO, Lazarus L 1989 The pharmacokinetics, safety and endocrine effects of authentic biosynthetic human growth hormone in normal subjects. Clin Endocrinol (Oxf) 30:335-345
27. Sotiropoulos A, Moutoussamy S, Renaudie F, Clauss M, Kayser C, Gouilleux F, Kelly PA, Finidori J 1996 Differential activation of Stat3 and Stat5 by distinct regions of the growth hormone receptor. Mol Endocrinol 10:998-1009
28. Gouilleux F, Wakao H, Mundt M, Groner B 1994 Prolactin induces phosphorylation of Tyr694 of Stat5 (MGF), a prerequisite for DNA binding and induction of transcription. EMBO J 13:4361-4369
29. Maamra M, Finidori J, Von Laue S, Simon S, Justice S, Webster J, Dowers S, Ross R 1999 Studies with a growth hormone antagonist and dual-fluorescent confocal microscopy demonstrate that the full-length human growth receptor, but not the truncated isoform, is very rapidly internalized independent of Jak2-Stat5 signaling. J Biol Chem 274:14791-14798
30. von Laue S, Finidori J, Maamra M, Shen X-Y, Justice S, Dobson PRM, Ross RJM 2000 Stimulation of endogenous GH and interleukin-6 receptors selectively activates different Jaks and Stats, with a Stat5 specific synergistic effect of dexamethasone. J Endocrinol 165:301-311
31. Harder KW, Owen P, Wong LK, Aebersold R, Clark-Lewis I, Jirik FR 1994 Characterization and kinetic analysis of the intracellular domain of human protein tyrosine phosphatase β (HPTP β) using synthetic phosphopeptides. Biochem J 298:395-401
32. Swarup G, Cohen S, Garbers DL 1982 Inhibition of membrane phosphotyrosyl-protein phosphatase activity by vanadate. Biochem Biophys Res Commun 107:1104-1109
33. Huyer G, Liu S, Kelly J, Moffat J, Payette P, Kennedy B, Tsaprailis G, Gresser MJ, Ramachandran C 1997 Mechanism of inhibition of protein-tyrosine phosphatases by vanadate and pervanadate. J Biol Chem 272:843-851
34. Leung K-C 2004 Regulation of cytokine receptor signaling by nuclear hormone receptors: a new paradigm for receptor interaction. DNA Cell Biol 23:463-474
35. Adams TE, Hansen JA, Starr R, Nicola NA, Hilton DJ, Billestrup N 1998 Growth hormone preferentially induces the rapid, transient expression of SOCS-3, a novel inhibitor of cytokine receptor signaling. J Biol Chem 273:1285-1287
36. Hovey RC, Trott JF, Vonderhaar BK 2002 Establishing a framework for the functional mammary gland: from endocrinology to morphology. J Mammary Gland Biol Neoplasia 7:17-38
37. Divisova J, Kuiatse I, Lazard Z, Wieiss H, Vreeland F, Hadsell DL, Schiff R, Osborne CK, Lee AV 2006 The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth. Breast Cancer Res Treat 98:315-327
38. Thordarson G, Semaan S, Low C, Ochoa D, Leong H, Rajkumar L, Guzman RC, Nandi S, Talamantes F 2004 Mammary tumorigenesis in growth hormone deficient spontaneous dwarf rats; effects of hormonal treatments. Breast Cancer Res Treat 87:277-290
39. Gil-Puig C, Blanco M, Carcía-Caballero T, Segura C, Pérez-Fernánadez R 2002 Pit-1/GHF-1 and GH expression in the MCF-7 human breast adenocarcinoma cell line. J Endocrinol 173:161-167
40. Chopin LK, Veveris-Lowe TL, Philipps AF, Herington AC 2002 Co-expression of GH and GHR isoforms in prostate cancer cell lines. Growth Horm IGF Res 12:126-136
41. Chiarugi P, Cirri P 2003 Redox regulation of protein tyrosine phosphatases during receptor tyrosine kinase signal transduction. Trend Biochem Sci 28:509-514
42. Lim JS, Frenkel K, Troll W 1992 Tamoxifen suppresses tumor promoterinduced hydrogen peroxide formation by human neutrophils. Cancer Res 52:4969-4972
43. Wassmann S, Laufs U, Stamenkovic D, Linz W, Stasch J-P, Ahlbory K, Rösen R, Böhm M, Nickenig G 2002 Raloxifene improves endothelial dysfunction in hypertension by reduced oxidative stress and enhanced nitric oxide production. Circulation 105:2083-2091
44. Riggs L, Hartmann LC 2003 Selective estrogen-receptor modulators - mechanisms of action and application to clinical practice. N Engl J Med 348:618-629
45. Levenson AS, Svoboda KM, Pease KM, Kaiser SA, Chen B, Simons LA, Jovanovic BD, Dyck PA, Jordan VC 2002 Gene expression profiles with activation of the estrogen receptor α-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor. Cancer Res 62:4419-4426
46. Frasor J, Stossi F, Danes JM, Komm B, Lyttle CR, Katzenellenbogen BS 2004 Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. Cancer Res 64:1522-15333
47. Tee MK, Rogatsky I, Tzagarakis-Foster C, Cvoro A, An J, Christy RJ, Yamamoto KR, Leitman DC 2004 Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors α and β. Mol Biol Cell 15:1262-1272